# Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

> **NCT06574360** · PHASE2 · RECRUITING · sponsor: **China Medical University Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** S1RA plus NMDAE
- **DRUG:** S1RA plus Placebo Cap

## Key facts

- **NCT ID:** NCT06574360
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2028-12
- **Final completion:** 2029-03
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06574360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06574360, "Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06574360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*